Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

医学 无容量 肺癌 肿瘤科 肿瘤浸润淋巴细胞 内科学 环磷酰胺 氟达拉滨 免疫疗法 免疫学 化疗 癌症
作者
Ben Creelan,Chao Wang,Jamie K. Teer,Eric M. Toloza,Jiqiang Yao,Sungjune Kim,Ana Marie Landin,John E. Mullinax,James Joseph Saller,Andreas Nicholas Saltos,David R. Noyes,Leighann B. Montoya,Wesley Curry,Shari Pilon‐Thomas,Alberto Chiappori,Tawee Tanvetyanon,Frederic J. Kaye,Zachary Thompson,Sean Yoder,Bin Fang
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:27 (8): 1410-1418 被引量:464
标识
DOI:10.1038/s41591-021-01462-y
摘要

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs administered with nivolumab in 20 patients with advanced non-small cell lung cancer following initial progression on nivolumab monotherapy. The primary end point was safety and secondary end points included objective response rate, duration of response and T cell persistence. Autologous TILs were expanded ex vivo from minced tumors cultured with interleukin-2. Patients received cyclophosphamide and fludarabine lymphodepletion, TIL infusion and interleukin-2, followed by maintenance nivolumab. The end point of safety was met according to the prespecified criteria of ≤17% rate of severe toxicity (95% confidence interval, 3–29%). Of 13 evaluable patients, 3 had confirmed responses and 11 had reduction in tumor burden, with a median best change of 35%. Two patients achieved complete responses that were ongoing 1.5 years later. In exploratory analyses, we found T cells recognizing multiple types of cancer mutations were detected after TIL treatment and were enriched in responding patients. Neoantigen-reactive T cell clonotypes increased and persisted in peripheral blood after treatment. Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer. Adoptive cell therapy with tumor-infiltrating lymphocytes in metastatic lung cancer patients is safe and elicits antitumor activity, including ongoing complete responses, in association with polyclonal T cell responses against tumor antigens.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
空空完成签到 ,获得积分10
刚刚
法则尔先生完成签到,获得积分10
刚刚
嗨嗨完成签到,获得积分10
刚刚
杏仁完成签到,获得积分10
刚刚
刘子田完成签到,获得积分10
刚刚
华仔的应助被实验室采纳,获得10
刚刚
123456hhh完成签到,获得积分10
1秒前
礐嶨完成签到,获得积分10
1秒前
完美世界的应助被Ha采纳,获得10
1秒前
Moonlight完成签到 ,获得积分10
1秒前
Orange的应助被xwj采纳,获得10
1秒前
李琛璐完成签到 ,获得积分10
1秒前
ZeKaWa的应助被森林木采纳,获得10
2秒前
发发完成签到,获得积分10
2秒前
2秒前
羊翊婕发布了新的文献求助10
2秒前
yuan发布了新的文献求助10
2秒前
冷静的远山完成签到 ,获得积分10
3秒前
GLUUUUUE完成签到 ,获得积分10
3秒前
離1028发布了新的文献求助10
3秒前
sunziyi完成签到,获得积分20
4秒前
张鹏荣发布了新的文献求助10
4秒前
TSUKI发布了新的文献求助10
4秒前
4秒前
小小完成签到 ,获得积分10
4秒前
呆萌道天完成签到,获得积分10
4秒前
5秒前
Akim的应助被liu采纳,获得10
5秒前
张小黑完成签到,获得积分10
5秒前
Antonio完成签到 ,获得积分0
5秒前
5秒前
5秒前
6秒前
6秒前
6秒前
6秒前
7秒前
7秒前
yu发布了新的文献求助10
7秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315